Search

Harmony Biosciences Holdings Inc

Gesloten

SectorGezondheidszorg

38.13 0.55

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

37.74

Max

38.79

Belangrijke statistieken

By Trading Economics

Inkomsten

43M

75M

Verkoop

46M

261M

K/W

Sectorgemiddelde

12.343

57.371

EPS

1.28

Winstmarge

28.87

Werknemers

293

EBITDA

53M

102M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+9.35% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

160M

2.2B

Vorige openingsprijs

37.58

Vorige sluitingsprijs

38.13

Harmony Biosciences Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 aug 2026, 22:31 UTC

Harmony Biosciences Holdings Inc. is trading higher in after-market hours, reaching the upper end of its one-month range and above the 20-day moving average.

20 aug 2026, 23:31 UTC

Harmony Biosciences Holdings Inc shares are higher in after-market trading, supported by strong momentum above the 20-day moving average and within its one-month range.

19 aug 2026, 19:56 UTC

Harmony Biosciences Holdings Inc. is trading higher, reaching a session high and remaining above its 20-day moving average during Wednesday's session.

14 aug 2026, 19:46 UTC

Harmony Biosciences shares are lower as the Pharmaceuticals sub-sector declines. The stock remains above its 20-day moving average, indicating some underlying strength.

13 aug 2026, 22:51 UTC

Harmony Biosciences shares are rising in after-market trading, supported by favorable macroeconomic indicators and a broader trend in major averages closing higher.

11 aug 2026, 19:21 UTC

Harmony Biosciences Holdings Inc. is trading higher today, continuing its upward trajectory since Monday's close amid broader market trends and rising oil prices.

10 aug 2026, 19:46 UTC

Harmony Biosciences Holdings Inc is trading higher, continuing its upward trend since Friday. The stock remains above its 20-day moving average.

7 aug 2026, 20:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower amid broader market declines and decreasing Treasury yields following recent economic data.

6 aug 2026, 23:51 UTC

Harmony Biosciences Holdings Inc shares declined during after-market hours, struggling to maintain earlier gains amid a lack of specific news to explain the movement.

5 aug 2026, 20:03 UTC

Social Media
Event
News

Harmony Biosciences shares are lower despite new Phase 1 data on BP-205. Truist maintains a Hold rating and raises the price target to $34.

4 aug 2026, 20:04 UTC

Social Media
News
Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

3 aug 2026, 23:11 UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

1 aug 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31 jul 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28 jul 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27 jul 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24 jul 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22 jul 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21 jul 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Peer Vergelijking

Prijswijziging

Harmony Biosciences Holdings Inc Prognose

Koersdoel

By TipRanks

9.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 41.63 USD  9.35%

Hoogste 55 USD

Laagste 30 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harmony Biosciences Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

8 ratings

3

Buy

4

Hold

1

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat